Polypharmacy

From Citizendium
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Polypharmacy is defined as "the use of multiple drugs administered to the same patient, most commonly seen in elderly patients. It includes also the administration of excessive medication."[1] Polypharmacy hinders patient compliance with medications and may increase drug-related side effects and adverse reactionss[2].

Taking 4 or more prescriptions daily is more common among low income patients according to one survey.[3] This occurs in 32% of patients with household income below $25,000; whereas this occurs in 12% of those with household income above $75,000.

Using 11 or more chronic medications is a risk factor for drug toxicity.[4]

Combining multiple medications into a single 'polypill' may help patients.[5]

However, taking "three drugs at half standard dose in combination" may be better than one drug at standard dose according to a systematic review.[6]

Reducing polypharmacy

Matching patients' medical problems and their medicines may identify unneeded or low priority drugs that can be discontinued.[7]

Delaying antibiotics for 48 hours while waiting on improvement of respiratory tract infections[8][9] or cystitis[10] may reduce antibiotic usage and reconsultation; however, this strategy may reduce patient satisfaction.

References

  1. National Library of Medicine. Polypharmacy. Retrieved on 2007-12-15.
  2. Muir AJ, Sanders LL, Wilkinson WE, Schmader K (2001). "Reducing medication regimen complexity: a controlled trial". J Gen Intern Med 16 (2): 77–82. DOI:10.1046/j.1525-1497.2001.016002077.x. PMID 11251757. Research Blogging. Full text at PubMed Central
  3. USA Today/Kaiser Family Foundation/Harvard School of Public Health Survey: the public on prescription drugs and pharmaceutical companies - kaiser family foundation. Retrieved March 10, 2008, from http://www.kff.org/kaiserpolls/pomr030408pkg.cfm.
  4. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K (2011). "High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice.". BMJ 342: d3514. DOI:10.1136/bmj.d3514. PMID 21693525. Research Blogging.
  5. "Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial". The Lancet In Press, Corrected Proof. DOI:10.1016/S0140-6736(09)60611-5. ISSN 0140-6736. Retrieved on 2009-03-31. Research Blogging.
  6. Law MR, Morris JK, Wald NJ (2009). "Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies". BMJ 338: b1665. PMID 19454737. PMC 2684577[e]
  7. Steinman MA, Hanlon JT (2010). "Managing medications in clinically complex elders: "There's got to be a happy medium".". JAMA 304 (14): 1592-601. DOI:10.1001/jama.2010.1482. PMID 20940385. Research Blogging.
  8. Spurling G, Del Mar C, Dooley L, Foxlee R (2007). "Delayed antibiotics for respiratory infections". Cochrane database of systematic reviews (Online) (3): CD004417. DOI:10.1002/14651858.CD004417.pub3. PMID 17636757. Research Blogging.
  9. Moore M, Little P, Rumsby K, Kelly J, Watson L, Warner G et al. (2009). "Effect of antibiotic prescribing strategies and an information leaflet on longer-term reconsultation for acute lower respiratory tract infection.". Br J Gen Pract 59 (567): 728-34. DOI:10.3399/bjgp09X472601. PMID 19843421. PMC PMC2751917. Research Blogging.
  10. Little P, Turner S, Rumsby K, et al (March 2009). "Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study". Health Technol Assess 13 (19): iii–iv, ix–xi, 1–73. DOI:10.3310/hta13190. PMID 19364448. Research Blogging.